|Bid||19.90 x 0|
|Ask||19.95 x 0|
|Day's Range||19.20 - 20.18|
|52 Week Range||6.31 - 24.75|
|Beta (3Y Monthly)||3.96|
|PE Ratio (TTM)||110.56|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LEAMINGTON, ON , Oct. 15, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has completed its first shipment of cannabis oil to its Argentina -based subsidiary ABP, S.A. ("ABP" or the "Argentinean Company"), a pharmaceutical import and distribution company. In accordance with a previously announced supply agreement, the Company delivered 1,500 bottles of Aphria's renowned Rideau CBD oil, which were provided to Hospital de Pediatria Garrahan ("Hospital Garrahan" or the "Hospital"), a leading pediatric hospital located in Buenos Aires , for use in a clinical study focused on treating refractory epilepsy in children.
In just days, the entire country of Canada will allow recreational cannabis to be legally sold across the nation. This event also has a number of companies outside of the cannabisspace showing interest and getting involved. "The total global [cannabis] category could reach upwards of $200 billion, as suggested by Constellation Brands," said Stifel analyst Christopher Growe.
In the news release, Aphria Records Solid Revenue Growth in First Quarter of 2019, issued 12-Oct-2018 by Aphria Inc. over Cision, we are advised by the company that the increase in revenue YOY should be 117% rather than 217% as originally issued inadvertently. LEAMINGTON, ON , Oct. 12, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH or US OTC: APHQF) today reported its results, for the first quarter and quarter ended August 31, 2018 .
CORAL GABLES, FL / ACCESSWIRE / October 11, 2018 / Thecannabis industry is seeing the birth of strategic investments and new acquisitions this year. Ahead of Canada's national legalization of recreationalmarijuana next week, investors are laser focused on marijuana stocks. "With cannabis, you're talking about this massive step change in terms of the addressable market," Vivien Azer said on CNBC's "Squawk Box" on Wednesday.
LEAMINGTON, ON , Oct. 11, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH) (OTCQB: APHQF) and Drug Free Kids Canada ("Drug Free Kids" or "DFK") announced today that they have entered into a Charter Agreement (the "Agreement") focused on increasing educational awareness of the potential harms of cannabis for children and underage youth and the safe and responsible use of cannabis by adults. Aphria and Drug Free Kids are united by their shared values of keeping cannabis out of the hands of children and youth and raising awareness though effective educational campaigns. "As a leading global cannabis company, Aphria has consistently advocated for an education-led approach to keeping cannabis out of the hands of youth, while promoting the safe and responsible use of legal cannabis by adults," said Tamara Macgregor , Vice President of Communications for Aphria.
LEAMINGTON, ON , Oct. 10, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH or USOTCQB: APHQF) today responded to a request from the Investment Industry Regulatory Organization of Canada ("IIROC") regarding media reports suggesting the Company is engaged in discussions regarding a potential investment in Aphria. While Aphria engages in discussions with potential strategic partners and/or investors from time to time, the Company notes that there is no agreement, understanding or arrangement in place with a potential investor at this time. Aphria will advise the investment community of any material changes, if and when they occur, in accordance with applicable disclosure requirements.
NEW YORK, NY / ACCESSWIRE / October 2, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
LEAMINGTON, ON , Oct. 2, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) will release its first quarter results for 2019 on October 12, 2018 . Financial results are expected to be released at approximately 7:00am ET , through SEDAR and on Aphria's website at aphria.ca/investors. A conference call is scheduled for 9:00am ET and will feature a presentation by Aphria executives followed by a question and answer period with analysts.
LEAMINGTON, ON , Sept. 28, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today unveiled its comprehensive portfolio of adult-use brands that will be available for sale in the adult-use market. Backed by more than a year and a half of extensive qualitative and quantitative research, including focus groups and influencer consultations, the Company has developed a portfolio of brands designed to meet the needs of specific consumer segments. The brands feature a range of price points and offer a variety of product formats and consumption options tailored to consumer preferences.
Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) has closed its strategic sale of the Company’s Latin American and Caribbean assets to Aphria Inc. (APH.TO) (“Aphria”), a leading global cannabis company. This sale will provide Scythian with leverage for early stage investments in emerging U.S. markets.
OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), has entered into a letter of intent to acquire a 51 per cent stake in One Plant™, an adult-use cannabis retail operation led by members of the Serruya Family (the “Serruya Family”), including Aaron Serruya, the president of International Franchise Inc., which has over 4500 franchise locations in over 50 countries. Serruya Family has also been a leading force in the cannabis industry as early investors of Aphria (“TSX:APH”) and the majority shareholder of Liberty Health Sciences (“CNSX: LHS”).
LEAMINGTON, ON , Sept. 21, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has appointed John Sadler as the Company's Vice President of Investor Relations effective September 15, 2018 . Mr. Sadler brings more than 25 years of capital markets expertise to his new role at Aphria where he will be responsible for managing all of the Company's interactions with its institutional and retail equity investors as well as the sell-side analysts who publish research on the Company.
LEAMINGTON, ON , Sept. 20, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that its Australian-based partner Althea Company Pty Ltd. ("Althea" or the "Australian Company") has successfully completed the fund raising for its proposed listing on the Australian Securities Exchange ("ASX") via an Initial Public Offering ("IPO"). Demand for shares in Althea significantly exceeded the proposed maximum fund raising under the IPO of AUD$19.65 million. Aphria took a cornerstone position in the IPO by subscribing for an additional 17 million shares which has resulted in a 25% holding in Althea (AUD$3.4 million investment).
LEAMINGTON, ON , Sept. 20, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced they have signed supply agreements with official distributors in all ten provinces and one territory to provide high-quality, branded cannabis products for the adult-use market across the country come recreational cannabis legalization on October 17 th. With 28 days to legalization, Aphria has already begun shipping initial product orders to ensure an extensive range of products from the Company's expanding portfolio of adult-use brands will be available to consumers on October 17. Aphria's recreational brands Solei and RIFF will also be available through online and in-store retailers in all markets.
Shareholders Approve Name Change to SOL Investments Corp. TORONTO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) is pleased to announce the results of Scythian’s special meeting of shareholders on September 14, 2018 (“Special Meeting”).
LEAMINGTON, ON , Sept. 14, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that Dennis Staudt has resigned from the Company's Board of Directors (the "Board"). Mr. Staudt served as Lead Independent Director and Chair of the Audit Committee, and he had been a member of the Board since 2014, before the company was publicly traded.
Canada in particular is the focus as of late with a number of Canadian cannabis stocks benefiting in a big way from new highs in the market. According to estimates by cannabis researchers at ArcView Market Research in partnership with BDS Analytics, the latest revenue projections for the U.S. medical cannabis industry in 2018 is $4.3 billion versus $6.7 billion for adult use. Last year, medical marijuana sales came in just under $6 billion while adult use grabbed $2.6 billion.
LEAMINGTON, ON , Sept. 12, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has entered into a wholesale supply agreement with Emblem Cannabis Corp., wholly owned subsidiary of Emblem Corp. and a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("Emblem") to supply 175,000 kg of high-quality cannabis over a five-year period starting May 2019 (the "Agreement") with a total of 25,000 kg deliverable for the balance of the first year. Under the terms of the Agreement, Aphria will receive a non-refundable deposit of $22.8 million , which is comprised of $12.8 million in cash, and 6,952,169 of common shares of Emblem. "Aphria's total annualized production capabilities are about to reach 255,000kg in early 2019, which means we are not only well positioned to meet all of our supply commitments across Canada and anticipated international demand, but also have the capacity to support the projected demand through our partners," said Gregg Battersby , Vice President of Commercial Strategy at Aphria.
The legalization of cannabis is taking hold on a global scale and even CEO's like Tesla's (TSLA) Elon Musk appear to be taking a liking to new legislation. Investors are now looking to Canadian marijuana stocks as these have continued to reach new milestones over recent months. With the industry expecting continued to grow after Oct. 17, when weed will become legal across Canada for any purpose, a number of investors are looking to get a piece of the action.
LEAMINGTON, ON , Sept. 6, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has entered into a share purchase agreement with a group of buyers, each acting individually and not in concert, including a member of the Serruya family, and has completed the sale of 64,118,462 shares (the "Shares") in Liberty Health Sciences, Inc. ("Liberty"), representing 100% of the Company's outstanding investment in Liberty. As part of the transaction, Aphria retains an irrevocable option to repurchase the Shares or any replacement securities from the buyers for a period of up to five years, subject to the satisfaction of certain conditions as further described below.
The additional flowering rooms will increase total potential flowering capacity to 90,000 square feet and, assuming a current yield, will bring 7ACRES' annual production potential from 10,000kg to 13,330kg. "As the first coast-to-coast premium cannabis brand in Canada , 7ACRES is already one of the fastest scaling producers in the country. This flowering room expansion continues to increase our capacity and improve our ability to meet the demand of cannabis enthusiasts upon legalization of adult use cannabis in Canada ," said John Fowler , CEO of Supreme Cannabis. Completion of flowering rooms at the 342,000-square foot 7ACRES facility remains on schedule for completion in December 2018. With an annual production capacity expected to reach 50,000 kg once the 7ACRES facility is fully operational, the Company is committed to supplying premium-quality cannabis flower to the Canadian recreational market from coast-to-coast.
LEAMINGTON , ON and BURLINGTON, ON , Sept. 5, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) and Rapid Dose Therapeutics Inc. ("RDT"), a Canadian bio-technology company focused on innovative drug delivery solutions, announced today that they have signed a non-binding Memorandum of Understanding ("MOU") related to RDT's QuickStrip™ products. Under the terms of the MOU, the companies intend to enter into a definitive agreement in the near future pursuant to which RDT will provide Aphria with exclusive global preferred rights to produce, distribute and sell QuickStrip™ products for cannabis markets around the world.
LEAMINGTON, ON , Sept. 4, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) today announced that it has entered into a strategic partnership (the "Partnership") with Schroll Medical ('Schroll" or the "Danish Company"), a subsidiary of prominent European flower producer, Schroll Flowers. The Partnership will pursue the cultivation and worldwide distribution of organic, EU GMP-certified medical cannabis, and will be managed by the Company's wholly-owned subsidiary Aphria Deutschland GmbH ("Aphria Germany").
NEW YORK, NY / ACCESSWIRE / August 31, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...